Dr. Fleshner's clinical practice is in urologic oncology with research interests in prostate and bladder cancer.
Neil E Fleshner, MPH, MD, FRCSC
Clinician Investigator, Princess Margaret Cancer Centre
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Shared decision-making for men with BRCA2 mutations considering removal of their prostate in the absence of any disease
Study Status: Active
Study Purpose: This study aims to develop a “decision aid”. The decision aid will assist patients who have a BRCA2 genetic mutation in deciding between prostate surgery versus monitoring options with their urologist.
Background: Men with the BRCA2 gene are at risk of developing prostate cancer. These patients need to decide between having their prostate removed or monitoring their prostate health. Patient decisions aids have been effective in many other diseases to improve decision-making between patients and doctors. Decision aids present all current known information about a disease, all available treatment options and facts about treatment outcomes.
Study Methods: A total of 10 patients will be enrolled in this study. Eligible patients include those that have a known BRCA2 genetic mutation and are considering removing their prostate despite the absence of disease. Participation involves the completion of a 10-question survey on your opinions regarding the developed decision aid. An option to receive the decision aid and complete the survey online is available via email.
Health Conditions: Cancer
Clinician Investigator, Princess Margaret Cancer Centre
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Martin Barkin Chair, Division of Urology, Department of Surgery, University of Toronto
Professor, Department of Surgery, University of Toronto